Axsome Therapeutics, Inc. (NASDAQ:AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced presentations of new data on AXS-12 and solriamfetol at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), being held June 14-17, 2026, in Baltimore, Maryland.

Details of the presentations are as follows:

  • Title: Cognitive and Functional Outcomes from the Phase 3 Open-Label Extension and Randomized-Withdrawal ENCORE Trial of AXS-12 in Narcolepsy with Cataplexy

    Presentation Date and Time: Monday, June 15, 10:00 - 11:45 a.m. ET

    Lead Author: Bruce Corser MD, FAASM, Medical Director of Intrepid Research, Cincinnati, OH

    Poster Presentation Session: P-16

    Poster Number: 375
  • Title: Solriamfetol for Excessive Daytime Sleepiness in Narcolepsy and OSA: Post-hoc Multi-dimensional Composite Endpoint Analysis of Phase 3 Trials

    Presentation Date and Time: Monday, June 15, 10:00 - 11:45 a.m. ET

    Lead Author: Ellen Wertmer, FNP-BC, DBSM, FAASM, Founder of Restorative Sleep Medicine, Charlottesville, VA

    Poster Presentation Session: P-16

    Poster Number: 386
  • Title: Symptom Burden and Quality of Life in Patients with Narcolepsy Who Experience Residual Cataplexy: Subgroup Analysis from the CRESCENDO Survey

    Presentation Date and Time: Tuesday, June 16, 10:00 - 11:45 a.m. ET

    Lead Author: Michael Thorpy, MD, Director of the Sleep-Wake Disorders Center at the Montefiore Medical Center and Professor of Neurology at Albert Einstein College of Medicine, New York, NY

    Poster Presentation Session: P-34

    Poster Number: 316